Literature DB >> 21932011

Barth syndrome diagnosed in the subclinical stage of heart failure based on the presence of lipid storage myopathy and isolated noncompaction of the ventricular myocardium.

Atsuhito Takeda1, Akira Sudo, Masafumi Yamada, Hirokuni Yamazawa, Gaku Izumi, Ichizo Nishino, Tadashi Ariga.   

Abstract

Barth syndrome (BTHS) is an X-linked disorder characterized by skeletal myopathy, neutropenia, growth delay, and cardiomyopathy. It is caused by mutations in the tafazzin gene (TAZ). Although early diagnosis is critical to prevent the progression of heart failure, this disease remains unrecognized when heart failure is not clinically significant. Here we report on a 13-year-old boy with no family history of BTHS who was diagnosed with the syndrome in the subclinical stage of heart failure. The clues to the diagnosis of BTHS in this patient were the findings of lipid storage myopathy in the skeletal muscle biopsy, elevated plasma brain natriuretic peptide, and the diagnosis of isolated noncompaction of the ventricular myocardium in echocardiography. Genetic studies of TAZ revealed a disease-causing mutation (p.Gly216Arg) in this patient. Physicians should be aware of the possibility of this disease and carry out genetic studies when it is considered.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21932011     DOI: 10.1007/s00431-011-1576-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  15 in total

1.  Barth syndrome may be due to an acyltransferase deficiency.

Authors:  A F Neuwald
Journal:  Curr Biol       Date:  1997-08-01       Impact factor: 10.834

Review 2.  Cardiac manifestations of neuromuscular disorders in children.

Authors:  Daphne T Hsu
Journal:  Paediatr Respir Rev       Date:  2009-11-18       Impact factor: 2.726

3.  X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria.

Authors:  R I Kelley; J P Cheatham; B J Clark; M A Nigro; B R Powell; G W Sherwood; J T Sladky; W P Swisher
Journal:  J Pediatr       Date:  1991-11       Impact factor: 4.406

Review 4.  Cardiolipin metabolism and Barth Syndrome.

Authors:  Kristin D Hauff; Grant M Hatch
Journal:  Prog Lipid Res       Date:  2006-01-18       Impact factor: 16.195

5.  Genetic analysis of the G4.5 gene in families with suspected Barth syndrome.

Authors:  A M Cantlay; K Shokrollahi; J T Allen; P W Lunt; R A Newbury-Ecob; C G Steward
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

6.  Cardiac and clinical phenotype in Barth syndrome.

Authors:  Carolyn T Spencer; Randall M Bryant; Jane Day; Iris L Gonzalez; Steven D Colan; W Reid Thompson; Julie Berthy; Sharon P Redfearn; Barry J Byrne
Journal:  Pediatrics       Date:  2006-07-17       Impact factor: 7.124

7.  Neutrophils in Barth syndrome (BTHS) avidly bind annexin-V in the absence of apoptosis.

Authors:  Taco W Kuijpers; Nikolai A Maianski; Anton T J Tool; Kolja Becker; Barbara Plecko; Fredoen Valianpour; Ron J A Wanders; Rob Pereira; Johan Van Hove; Arthur J Verhoeven; Dirk Roos; Frank Baas; Peter G Barth
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

8.  Cardiomyopathy of unknown etiology: Barth syndrome unrecognized.

Authors:  Robert T Sweeney; Gregory J Davis; Jacqueline A Noonan
Journal:  Congenit Heart Dis       Date:  2008 Nov-Dec       Impact factor: 2.007

9.  Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth.

Authors:  C G Steward; R A Newbury-Ecob; R Hastings; S F Smithson; B Tsai-Goodman; O W Quarrell; W Kulik; R Wanders; M Pennock; M Williams; J L Cresswell; I L Gonzalez; P Brennan
Journal:  Prenat Diagn       Date:  2010-10       Impact factor: 3.050

10.  A novel X-linked gene, G4.5. is responsible for Barth syndrome.

Authors:  S Bione; P D'Adamo; E Maestrini; A K Gedeon; P A Bolhuis; D Toniolo
Journal:  Nat Genet       Date:  1996-04       Impact factor: 38.330

View more
  5 in total

Review 1.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

2.  Neutropenia in Barth syndrome: characteristics, risks, and management.

Authors:  Colin G Steward; Sarah J Groves; Carolyn T Taylor; Melissa K Maisenbacher; Birgitta Versluys; Ruth A Newbury-Ecob; Hulya Ozsahin; Michaela K Damin; Valerie M Bowen; Katherine R McCurdy; Michael C Mackey; Audrey A Bolyard; David C Dale
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

Review 3.  Barth syndrome.

Authors:  Sarah L N Clarke; Ann Bowron; Iris L Gonzalez; Sarah J Groves; Ruth Newbury-Ecob; Nicol Clayton; Robin P Martin; Beverly Tsai-Goodman; Vanessa Garratt; Michael Ashworth; Valerie M Bowen; Katherine R McCurdy; Michaela K Damin; Carolyn T Spencer; Matthew J Toth; Richard I Kelley; Colin G Steward
Journal:  Orphanet J Rare Dis       Date:  2013-02-12       Impact factor: 4.123

Review 4.  Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach.

Authors:  Stacey Reynolds
Journal:  J Multidiscip Healthc       Date:  2015-07-29

5.  MELAS syndrome due to the m.3291T > C mutation.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Mol Genet Metab Rep       Date:  2016-04-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.